RS52192B - The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases - Google Patents
The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseasesInfo
- Publication number
- RS52192B RS52192B RS20120014A RSP20120014A RS52192B RS 52192 B RS52192 B RS 52192B RS 20120014 A RS20120014 A RS 20120014A RS P20120014 A RSP20120014 A RS P20120014A RS 52192 B RS52192 B RS 52192B
- Authority
- RS
- Serbia
- Prior art keywords
- seq
- polypeptide
- amino acids
- amino acid
- mutein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05104863 | 2005-06-03 | ||
US68805705P | 2005-06-07 | 2005-06-07 | |
PCT/EP2006/062864 WO2006128911A2 (en) | 2005-06-03 | 2006-06-02 | Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
RS52192B true RS52192B (en) | 2012-10-31 |
Family
ID=35058651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20120014A RS52192B (en) | 2005-06-03 | 2006-06-02 | The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases |
Country Status (17)
Country | Link |
---|---|
US (1) | US8128920B2 (es) |
EP (1) | EP1888100B1 (es) |
JP (1) | JP5048658B2 (es) |
AT (1) | ATE530227T1 (es) |
AU (1) | AU2006254106B2 (es) |
CA (1) | CA2610691C (es) |
CY (1) | CY1112128T1 (es) |
DK (1) | DK1888100T3 (es) |
ES (1) | ES2376534T3 (es) |
HR (1) | HRP20110788T1 (es) |
IL (1) | IL187839A (es) |
NO (1) | NO339540B1 (es) |
PL (1) | PL1888100T3 (es) |
PT (1) | PT1888100E (es) |
RS (1) | RS52192B (es) |
SI (1) | SI1888100T1 (es) |
WO (1) | WO2006128911A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
JP4216950B2 (ja) * | 1998-09-01 | 2009-01-28 | 株式会社林原生物化学研究所 | インターロイキン−18結合蛋白質 |
CA2340579A1 (en) | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
PE20011350A1 (es) * | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
KR20040030625A (ko) * | 2001-05-25 | 2004-04-09 | 아레스 트레이딩 에스.에이. | Cns 손상을 치료하거나 예방하기 위한 il-18저해물질의 용도 |
JP5074030B2 (ja) | 2003-05-13 | 2012-11-14 | メルク セローノ ソシエテ アノニム | Il−18結合タンパク質の活性変異体とその医学的応用 |
-
2006
- 2006-06-02 JP JP2008514119A patent/JP5048658B2/ja active Active
- 2006-06-02 DK DK06763485.7T patent/DK1888100T3/da active
- 2006-06-02 AU AU2006254106A patent/AU2006254106B2/en active Active
- 2006-06-02 WO PCT/EP2006/062864 patent/WO2006128911A2/en active Application Filing
- 2006-06-02 CA CA2610691A patent/CA2610691C/en active Active
- 2006-06-02 PL PL06763485T patent/PL1888100T3/pl unknown
- 2006-06-02 ES ES06763485T patent/ES2376534T3/es active Active
- 2006-06-02 AT AT06763485T patent/ATE530227T1/de active
- 2006-06-02 US US11/915,913 patent/US8128920B2/en active Active
- 2006-06-02 RS RS20120014A patent/RS52192B/en unknown
- 2006-06-02 PT PT06763485T patent/PT1888100E/pt unknown
- 2006-06-02 SI SI200631215T patent/SI1888100T1/sl unknown
- 2006-06-02 EP EP06763485A patent/EP1888100B1/en active Active
-
2007
- 2007-12-03 IL IL187839A patent/IL187839A/en active IP Right Grant
- 2007-12-11 NO NO20076387A patent/NO339540B1/no unknown
-
2011
- 2011-10-27 HR HR20110788T patent/HRP20110788T1/hr unknown
- 2011-11-30 CY CY20111101178T patent/CY1112128T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2610691C (en) | 2015-12-01 |
ES2376534T3 (es) | 2012-03-14 |
HRP20110788T1 (hr) | 2011-11-30 |
EP1888100B1 (en) | 2011-10-26 |
NO339540B1 (no) | 2016-12-27 |
CY1112128T1 (el) | 2015-11-04 |
PL1888100T3 (pl) | 2012-03-30 |
DK1888100T3 (da) | 2012-01-23 |
US8128920B2 (en) | 2012-03-06 |
IL187839A0 (en) | 2008-03-20 |
JP5048658B2 (ja) | 2012-10-17 |
US20080233085A1 (en) | 2008-09-25 |
AU2006254106B2 (en) | 2012-04-26 |
WO2006128911A2 (en) | 2006-12-07 |
JP2008542340A (ja) | 2008-11-27 |
WO2006128911A3 (en) | 2007-03-29 |
SI1888100T1 (sl) | 2012-01-31 |
AU2006254106A1 (en) | 2006-12-07 |
CA2610691A1 (en) | 2006-12-07 |
PT1888100E (pt) | 2011-12-15 |
AU2006254106A8 (en) | 2008-04-03 |
IL187839A (en) | 2013-03-24 |
ATE530227T1 (de) | 2011-11-15 |
EP1888100A2 (en) | 2008-02-20 |
NO20076387L (no) | 2008-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tan et al. | Venom-gland transcriptome and venom proteome of the Malaysian king cobra (Ophiophagus hannah) | |
HRP20161807T1 (hr) | Produljeni rekombinantni polipeptidi i sastavi koji ih sadrže | |
DE69717092T2 (de) | Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid | |
US20150111821A1 (en) | Mutated fibroblast growth factor (fgf) 1 and methods of use | |
Rodrigues et al. | Bactericidal and neurotoxic activities of two myotoxic phospholipases A2 from Bothrops neuwiedi pauloensis snake venom | |
DE69628576T2 (de) | Procollagene | |
CN103415300A (zh) | N-末端修饰的fgf21化合物 | |
US20090305352A1 (en) | Activated collagen scaffold materials and their special fused active restoration factors | |
AR071127A1 (es) | Metodos de uso de un receptor acoplado a proteina g para identificar secretagogos del peptido yy(pyy) y compuestos utiles en el tratamiento de afecciones moduladas por pyy | |
WO2013006486A3 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
NZ596778A (en) | Glucose-regulating polypeptides and methods of making and using same | |
AR040446A1 (es) | Defensinas de plantas | |
DE112005000737T5 (de) | Mit Heparansulfat-Zuckerketten modifizierte Heparin-bindende Proteine, Verfahren zur Erzeugung derselben und Arzneimittel, welche dieselben enthalten | |
HRP20100644T1 (hr) | Cijepivo kombinacije peptida protiv alergije na macke | |
JPH08503198A (ja) | Op−3誘導形態形成 | |
JP2005511614A (ja) | 新規な上皮細胞増殖因子タンパク質及び遺伝子、及びその使用方法 | |
WO2015061331A1 (en) | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use | |
JP5992529B2 (ja) | ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物 | |
JP2010508845A (ja) | ヘパリン結合配列に融合した増殖因子を使用して心臓修復を促進する方法 | |
Miele et al. | Expression of Bv8 in Pichia pastoris to identify structural features for receptor binding | |
RS52192B (en) | The use of IL-18BP isoforms for the therapy and / or prevention of neurologic inflammatory diseases | |
AR087719A2 (es) | Celula de planta transformada, cultivo de tejidos y planta transgenica | |
JPH0995454A (ja) | 抗潰瘍組成物 | |
Liu et al. | The repairing effect of a recombinant human connective‐tissue growth factor in a burn‐wounded rhesus‐monkey (Macaca mulatta) model | |
ATE338770T1 (de) | Mit bh4 fusionierte polypeptide |